Jingxin Pharmaceutical Co., Ltd (SHE: 002020), a Chinese pharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its Category 1 drug, Didaxini. This drug is a partial agonist of GABAA (γ-aminobutyric acid A) receptors and selectively targets the α1 subtype of benzodiazepine receptors with high affinity and a moderate agonistic effect, leading to rapid onset and maintenance of sleep.
Didaxini offers significant advantages over traditional benzodiazepine GABA receptor full agonists in terms of adverse reactions, including reduced risks of dyskinesia, sequelae effects, tolerance, ethanol interaction, physical dependence, and memory impairment. According to the public release, Didaxini was newly included in the narcotics and psychotropic substances catalog Category II in September this year.- Flcube.com
